Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger J Pomerantz

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
The Journal of Clinical Investigation|January 5, 2005
IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAARTFeng-Xiang Wang, Yan Xu, Julie Sullivan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 21, 2004
Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248)Mary A Vogler, Hedy Teppler, Rebecca Gelman, et al.
The Journal of Infectious Diseases|February 25, 2016
A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile InfectionSahil Khanna, Darrell S Pardi, Colleen R Kelly, et al.
Gastroenterology|August 9, 2020
A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative ColitisMatthew R Henn, Edward J O'Brien, Liyang Diao, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 8, 2020
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 TrialBarbara H McGovern, Christopher B Ford, Matthew R Henn, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
The Journal of Clinical Investigation|January 5, 2005
IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAARTFeng-Xiang Wang, Yan Xu, Julie Sullivan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 21, 2004
Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248)Mary A Vogler, Hedy Teppler, Rebecca Gelman, et al.
The Journal of Infectious Diseases|February 25, 2016
A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile InfectionSahil Khanna, Darrell S Pardi, Colleen R Kelly, et al.
Gastroenterology|August 9, 2020
A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative ColitisMatthew R Henn, Edward J O'Brien, Liyang Diao, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 8, 2020
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 TrialBarbara H McGovern, Christopher B Ford, Matthew R Henn, et al.
Pageof 9